SKSalih Suha Koparal

Salih Suha Koparal

*This is an algorithmically generated author record based on publicly available information.

Salih Suha Koparal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study

    by Derya Köseoğlu, Salih Suha Koparal, Özden Özdemi̇r Başer, Dilek Berker

    The aim of this study was to evaluate the effects of 6-months treatment with exenatide on lipid profile, high sensitivity C-reactive protein (hsCRP), carotid intima media thickness (CIMT), visceral adiposity and non-alcoholic fatty liver disease (NAFLD), which are all important cardiovascular risk factors. This study included 45 obese patients with type 2 diabetes mellitus (T2DM). The baseline clinical findings, laboratory parameters and ultrasonography findings were recorded. Exenatide twice daily recipe was given to these patients and after 6 months of therapy the same variables were compared. The compared parameters were lipid profiles, hsCRP, aspartat aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, liver craniocaudal diameter, visceral fat volume, subcutaneous fat thickness and CIMT. Liver diameter, visceral fat volume and subcutaneous fat thickness and CIMT were measured with ultrasonography. After therapy, statistically significant improvement were achieved in lipid profile, hsCRP, liver enzymes, body mass index, waist and hip circumferences. Also statistically significant decrease were obtained in liver craniocaudal diameter, subcutaneous fat thickness, visceral fat volume and CIMT. The reduction of CIMT and liver diameter were not correlated with BMI and HbA1c reduction. This study showed improvement in lipid profile and hsCRP levels with exenatide treatment. We also showed decrease in both visceral fat volume and subcutaneous fat thickness. We demonstrated significant decrease in liver enzymes with significant decrease in liver diameter. These findings supports the use of exenatide in patients with NAFLD and T2DM. Additionally this study showed that twice daily exenatide treatment reduces CIMT in obese T2DM patients.


  • Open Access

    Comparison of the clinical and sonographic effects of ultrasound therapy, extracorporeal shock wave therapy, and Kinesio taping in lateral epicondylitis

    by Tarık ÖZMEN, Salih Süha Koparal, Özlem Karataş, Filiz Eser, Bülent Özkurt, Ümit Gafuroğlu

    The aim of this study was to compare the clinical and sonographic effects of the ultrasound (US) therapy, extracorporeal shock wave therapy (ESWT), and Kinesio taping (KT) in the lateral epicondylitis (LE). A total of 40 patients with LE were included in the present study. The patients were randomly assigned to three treatment groups: US (n = 13), ESWT (n = 14), and KT (n = 13) groups. The visual analog scale (VAS) scores significantly decreased in all groups (p < 0.05). Grip strength significantly increased after eight weeks in only the KT group (p < 0.05). The Patient-Rated Tennis Elbow Evaluation Scale (PRTEE) scores significantly decreased after two weeks and after eight weeks in the US and ESWT groups and after eight weeks in the KT group (p < 0.05). The common extensor tendon (CET) thicknesses significantly decreased after eight weeks in only the ESWT group (p < 0.05). The US therapy, KT, and ESWT are effective in reducing pain and improving functionality. However, none of these treatment methods were found to be superior to the others in reducing the pain and improving functionality.